StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Arcus Biosciences — Total current liabilities by Year

Arcus Biosciences — Total current liabilities ($M) ($M)

Gilead Sciences Arcus Biosciences — Total current liabilities: $231M in FY2025, up 2.2% from a year earlier.

Latest, FY2025
231
Period ended Dec 31, 2025
Change on a year earlier
+2.2%
226 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below

Where the FY2025 figure comes from

Source: Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗

Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedArcus Biosciences — Total current liabilities ($M) ($M)Year on yearSource
FY2025Dec 31, 2025231+2.2%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
FY2024Dec 31, 2024226+22.8%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
FY2023Dec 31, 2023184-4.7%Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗
FY2022Dec 31, 2022193+16.3%Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗
FY2021Dec 31, 2021166+36.4%SEC Filing ↗
FY2020Dec 31, 2020122+436.1%SEC Filing ↗
FY2019Dec 31, 201922.7–SEC Filing ↗

Cite this data

StockData. (2026). Gilead Sciences Arcus Biosciences — Total current liabilities ($M), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-liab-cur

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.